Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the effect of MEDI4736 in combination with olaparib on Disease Control Rate in patients with selected advanced solid tumors To assess the safety and tolerability of MEDI4736 in combination with olaparib in patients with selected advanced solid tumors
Critère d'inclusion
- The 4 initial exploratory cohorts will include patients with:
- - relapsed small cell lung cancer (SCLC)
- - germline BRCA mutated (gBRCAm) metastatic human epidermal growth factor receptor 2 (HER2)-negative breast cancer
- - gBRCAm platinum sensitive relapsed ovarian cancer and
- gastric cancer